1-[1-(4-chlorophenyl)cyclobutyl]-2-bromoethanone | 106081-78-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[1-(4-chlorophenyl)cyclobutyl]-2-bromoethanone
• 英文别名: 2-bromo-1-[1-(4-chlorophenyl)cyclobutyl]ethanone；2-bromo-1-[1-(4-chloro-phenyl)-cyclobutyl]-ethanone；2-bromo-1-[l-(4-chloro-phenyl)-cyclobutyl]-ethanone；2-Bromo-1-[1-(4-chlorophenyl)-cyclobutyl]ethanone
• CAS: 106081-78-1
• 化学式: C₁₂H₁₂BrClO
• 分子量: 287.584
• InChiKey: YPEWWCINWMJFRK-UHFFFAOYSA-N

物化性质

• 沸点：
  359.8±32.0 °C(Predicted)
• 密度：
  1.513±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-[1-(4-chlorophenyl)cyclobutyl]-2-bromoethanone 在 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 1-(1-(4-chlorophenyl)cyclobutyl)-2-(4-methyl-4H-1,2,4-triazol-3-ylsulfinyl)ethanone
  参考文献：
  名称：

  [EN] 1 IBETA- HYDROXYSTEROID DEHYDROGENASE INHIBITORS
  [FR] COMPOSÉ

  摘要：

  公开号：

  WO2009106817A3
• 作为产物：
  描述：

  1-[1-(4-chlorophenyl)cyclobutyl]ethanone 在 溴 作用下， 以 甲醇 、 氯仿 为溶剂， 生成 1-[1-(4-chlorophenyl)cyclobutyl]-2-bromoethanone
  参考文献：
  名称：

  Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use

  摘要：

  公式I的化合物包括其药用可接受盐的单体对映体、混合物或其他对映体混合物，其中Ar为苯基、萘基或苯并噻吩基，每种基可选择性地被取代；R1和R2，可能相同也可能不同，分别为a）H、b）含有1至6个碳原子的烷基基团、c）含有3至6个碳原子的烯基基团、d）含有3至7个碳原子的环烷基基团、e）环中含有3至7个碳原子的环烷基基团、f）可选择性取代的芳基或杂环芳基、g）可选择性取代的芳基烷基或杂环芳基烷基；或者R1和R2形成一个由1至3个碳原子的烷基基团选择性取代的烷基链，与它们连接的原子一起形成一个5或6元环；R3为a）H、b）可选择性取代的芳基或杂环芳基、c）可选择性取代的芳基甲基基团；或者d）含有3至6个碳原子的烷氧基烷基基团；而R4和R5，可能相同也可能不同，独立地为含有1至3个碳原子的烷基基团，或者R4和R5与它们连接的原子一起形成一个含有3至6个碳原子的环烷基环；描述了制备这种化合物的过程；含有这种化合物的组合物及其在治疗抑郁症、焦虑症、帕金森病、肥胖症、认知障碍、癫痫、神经系统疾病和作为神经保护剂中的用途。

  公开号：

  US06187802B1

文献信息

• Ligands for monoamine receptors and transporters, and methods of use thereof
  申请人：——

  公开号：US20030050309A1

  公开（公告）日：2003-03-13

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将这些杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺、5-羟色胺或去甲肾上腺素转运体。本发明的化合物将用于治疗许多困扰哺乳动物的疾病、症状和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖、呕吐、精神病、精神分裂症、帕金森病、炎症性疼痛、神经病性疼痛、Lesche-Nyhane病、威尔逊病和抽动症。本发明的另一个方面涉及合成这些杂环化合物的组合式库以及对这些库进行生物活性筛选，例如在基于多巴胺转运体的测定中。
• Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter
  申请人：Aquila M. Brian

  公开号：US20050080078A1

  公开（公告）日：2005-04-14

  One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

  本发明的一个方面涉及一种治疗哺乳动物药物成瘾或药物依赖的方法，包括向需要的哺乳动物施用治疗有效量的杂环化合物的步骤，例如，3-取代哌啶。在一个优选实施例中，本发明的方法治疗可卡因成瘾或甲基苯丙胺成瘾。
• Arylcyclobutylmethylamines
  申请人：Boots Company, PLC

  公开号：US04925879A1

  公开（公告）日：1990-05-15

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof; in which R.sub.1 and R.sub.2, which are the same or different, are H or an optionally substituted hydrocarbon group or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; R.sub.3 is an optionally substituted aromatic hydrocarbon group; and R.sub.4 is a hydrocarbon group containing at least one substituent selected from the group consisting of hydroxy and acylated derivatives thereof, optionally substituted alkoxy groups, optionally substituted cycloalkyloxy groups, optionally substituted alkylenedioxy groups, oxo and groups of formula S(O).sub.p R.sub.5 in which p is 0, 1 or 2 and R.sub.5 is an alkyl group, said hydrocarbon group being optionally substituted by additional substituents, are useful in the treatment of depression.

  化学式I的化合物及其药学上可接受的盐；其中R.sub.1和R.sub.2，它们相同或不同，是H或一个可选地取代的碳氢基团，或者R.sub.1和R.sub.2与它们连接的氮原子一起形成一个可选地取代的杂环环；R.sub.3是一个可选地取代的芳香碳氢基团；R.sub.4是一个含有至少一种亲水基团或酰化衍生物的碳氢基团，可选地取代的烷氧基团，可选地取代的环烷氧基团，可选地取代的烷二氧基基团，氧代基和化学式S（O）.sub.p R.sub.5中的基团，其中p为0、1或2，R.sub.5是一个烷基基团，所述碳氢基团可选地由额外的取代基团取代，在抑郁症的治疗中有用。
• Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use
  申请人：Knoll Aktiengesellschaft

  公开号：US06187802B1

  公开（公告）日：2001-02-13

  Compounds of Formula I including pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which Ar is phenyl, naphthyl or benzo[b]thiophenyl, each of which may be optionally substituted; R1 and R2, which may be the same or different, independently are a) H, b) an alkyl group containing 1 to 6 carbon atoms, c) an alkenyl group containing 3 to 6 carbon atoms, d) a cycloalkyl group containing 3 to 7 carbon atoms, e) a cycloalkylmethyl group in which the ring contains 3 to 7 carbon atoms, f) an aryl or heteroaryl group optionally substituted g) an arylalkyl or heteroarylalkyl group each optionally substituted; or R1 and R2 form an alkylene chain optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms, such that, together with the atoms to which they are attached, they form a 5 or 6 membered ring; R3 is a) H, b) an aryl or heteroaryl group each optionally substituted c) an optionally substituted arylmethyl group; or d) an alkoxyalkyl group containing 3 to 6 carbon atoms; and R4 and R5, which may be the same or different, independently are an alkyl group containing 1 to 3 carbon atoms, or R4 and R5 together with the atom to which they are attached form a cycloalkyl ring containing 3 to 6 carbon atoms; processes to prepare such compounds; compositions containing such compounds and their use in the treatment of depression, anxiety, Parkinson's disease, obesity, cognitive disorders, seizures, neurological disorders and as neuroprotective agents; are described.

  公式I的化合物包括其药用可接受盐的单体对映体、混合物或其他对映体混合物，其中Ar为苯基、萘基或苯并噻吩基，每种基可选择性地被取代；R1和R2，可能相同也可能不同，分别为a）H、b）含有1至6个碳原子的烷基基团、c）含有3至6个碳原子的烯基基团、d）含有3至7个碳原子的环烷基基团、e）环中含有3至7个碳原子的环烷基基团、f）可选择性取代的芳基或杂环芳基、g）可选择性取代的芳基烷基或杂环芳基烷基；或者R1和R2形成一个由1至3个碳原子的烷基基团选择性取代的烷基链，与它们连接的原子一起形成一个5或6元环；R3为a）H、b）可选择性取代的芳基或杂环芳基、c）可选择性取代的芳基甲基基团；或者d）含有3至6个碳原子的烷氧基烷基基团；而R4和R5，可能相同也可能不同，独立地为含有1至3个碳原子的烷基基团，或者R4和R5与它们连接的原子一起形成一个含有3至6个碳原子的环烷基环；描述了制备这种化合物的过程；含有这种化合物的组合物及其在治疗抑郁症、焦虑症、帕金森病、肥胖症、认知障碍、癫痫、神经系统疾病和作为神经保护剂中的用途。
• Arylcyclobutylmethylamine therapeutic agents
  申请人：The Boots Company Plc

  公开号：US05047432A1

  公开（公告）日：1991-09-10

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof; in which R.sub.1 and R.sub.2, which are the same or different, are H or an optionally substituted hydrocarbon group or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring; R.sub.3 is an optionally substituted aromatic hydrocarbon group; and R.sub.4 is a hydrocarbon group containing at least one substituent selected from the group consisting of hydroxy and acylated derivatives thereof, optionally substituted alkoxy groups, optionally substituted cycloalkyloxy groups, optionally substituted alkylenedioxy groups, oxo and groups of formula S(O).sub.p R.sub.5 in which p is 0, 1 or 2 and R.sub.5 is an alkyl group, said hydrocarbon group being optionally substituted by additional substituents, are useful in the treatment of depression.

  式I的化合物及其药学上可接受的盐；其中R1和R2相同或不同，是H或可选择性取代的碳氢基团，或R1和R2与它们附着的氮原子一起形成可选择性取代的杂环环；R3是可选择性取代的芳香碳氢基团；R4是含有至少一种取代基的碳氢基团，所述取代基选自羟基和其酰化衍生物，可选择性取代的烷氧基团，可选择性取代的环烷氧基团，可选择性取代的烷二氧基基团，氧代基和式S（O）pR5的基团，其中p为0、1或2，R5是烷基团，所述碳氢基团可选择性地被附加取代基取代，用于治疗抑郁症。